Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer

Fig. 4

Response to immunotherapy. Microbiome changes notable in responders to ICI. Normalized data is presented in log-adjusted relative abundances. Left panels show PLS-DA graphs from nasal, buccal and gut sites all showing a microbiome separation when comparing ICI responders vs nonresponders. (a) Taxonomic profiling of nasal samples identified notable enrichment in Finegoldia, of phylum Firmicutes, in responders to ICI (p = 0.0005). (b) Buccal analysis of ICI responders show enrichment in Megasphaera of phylum Firmicutes (p = 8.6 × 10− 03) and decrease in Actinobacillus of phylum Proteobacteria (p = 9.7 × 10− 03). (c) In the fecal samples of ICI responders, Clostridiales was enriched (phylum Firmicutes, p = 0.017875) and Rikenellaceae decreased (phylum Bacteroidetes, p = 0.016013)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us